# EDGAR Filing Document

**Accession Number:** 0001776353
**File Stem:** 0000921895-25-002780
**Filing Date:** 2025-10
**Character Count:** 7672
**Document Hash:** d7f87c39182a60791fc326313c537418
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002780.hdr.sgml**: 20251021

**ACCESSION NUMBER**: 0000921895-25-002780

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251021

**DATE AS OF CHANGE**: 20251021

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARTELO BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001621221
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 331220924
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90653
- **FILM NUMBER:** 251408175

**BUSINESS ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-925-7049

**MAIL ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REACTIVE MEDICAL INC.
- **DATE OF NAME CHANGE:** 20170207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KNIGHT KNOX DEVELOPMENT CORP.
- **DATE OF NAME CHANGE:** 20141001
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Farb Daniel Stuart
- **CENTRAL INDEX KEY:** 0001776353

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 100 ESSEX RD.
- **CITY:** CHESTNUT HILL
- **STATE:** MA
- **ZIP:** 02467

## Ex-1

Exhibit 1

**<u>Transactions in Securities of the Issuer Since the Filing of Amendment No. 2 to the Schedule 13D</u>**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;<u>Nature of the Transaction</u> | &nbsp;&nbsp; Securities<br> <u>Acquired/(Disposed)</u> | &nbsp;&nbsp; Price Per<br> <u>Security ($)</u> | &nbsp;&nbsp; Date of<br> <u>Transaction</u> |

---

**<u>DANIEL S. FARB</u>**

Sale of Common Stock (92,800) 3.9708 10/20/2025 <br> Sale of Common Stock (55,103) 3.5498 10/21/2025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**ARTELO BIOSCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, $0.001 par value per share**

*(Title of Class of Securities)*

**04301G607**

*(CUSIP Number)*

**RYAN NEBEL**<br>OLSHAN FROME WOLOSKY LLP<br>1325 Avenue of the Americas<br>New York NY 10019<br>212-451-2300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/20/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **04301G607** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Farb Daniel Stuart** | Name of reporting person<br>**Farb Daniel Stuart** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**16399.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**16399.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**16399.00** | Aggregate amount beneficially owned by each reporting person<br>**16399.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value per share

**(b) Name of Issuer:**
ARTELO BIOSCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) is hereby amended and restated to read as follows:

The aggregate percentage of Shares reported owned by the Reporting Person is based upon a denominator that is the sum of: (i) 1,555,493 Shares outstanding as of September 16, 2025, as disclosed in the Issuer's Corporate Presentation issued on September 17, 2025 that is available on the Issuer's website, (ii) 441,210 Shares issued pursuant to the Issuer's underwritten offering on October 1, 2025, as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2025, and (iii) 11,299 Shares underlying the $10 Warrants (as defined below) held by the Reporting Person.

As of the date hereof, the Reporting Person directly beneficially owns 16,399 Shares, including 11,299 Shares underlying the $10 Warrants, as further described below, constituting approximately 0.8% of the Shares outstanding.

As of the date hereof, the Reporting Person owns 11,299 warrants referencing 11,299 Shares, which have an exercise price of $10.00 per Share and expire in June 2030 (the "$10 Warrants"). The $10 Warrants are exercisable immediately, subject to the Beneficial Ownership Limitation (as defined below). A holder of the $10 Warrants may not exercise any such $10 Warrants to the extent that such exercise would result in the number of Shares beneficially owned by such holder and his or its affiliates exceeding 4.99% of the total number of Shares outstanding immediately after giving effect to the exercise, except that upon at least 61 days' prior notice from the holder to the Issuer, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of Shares outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation"). The Reporting Person's Beneficial Ownership Limitation is currently set at 4.99%. As of the date hereof, the Beneficial Ownership Limitation does not limit the exercise of any of the 11,299 $10 Warrants owned by the Reporting Person and the Reporting Person may be deemed to beneficially own the 11,299 Shares underlying the 11,299 $10 Warrants.

**(b)**
—

**(c)**
Item 5(c) is hereby amended and restated to read as follows:

The transaction in the securities of the Issuer by the Reporting Person since the filing of the Amendment No. 2 to the Schedule 13D are set forth in Exhibit 1 and incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Farb Daniel Stuart

**Signature:** /s/ Daniel S. Farb

**Name/Title:** Daniel S. Farb

**Date:** 10/21/2025